Why Biosafety Is Becoming a Boardroom Issue
June 2, 2026
For decades, biosafety lived primarily within the walls of the laboratory—managed by safety officers, addressed during audits, and often viewed as a compliance requirement rather than a strategic priority. That paradigm is shifting. As biological research accelerates and the consequences of incidents, including near misses, grow more visible, biosafety has moved beyond a technical discipline and into the realm of enterprise risk. Incidents now carry implications for operations, funding, governance, and reputation, making biosafety not just a laboratory concern, but a defining issue for leadership and the boardroom.
Today, biosafety is no longer just a technical function; it is increasingly a boardroom issue, driven by growing risk exposure, investor expectations, grant funding requirements tied to biosafety and biosecurity oversight, and the global implications of biological research. Organizations that fail to recognize this shift risk more than failed inspections; they are vulnerable to operational disruption, funding challenges, regulatory exposure, and erosion of stakeholder trust.
Risk Exposure Has Moved Up the Chain
Modern bioscience operates at unprecedented speed and complexity. Advanced therapeutics, synthetic biology, and global collaboration have expanded both opportunity and risk, making biosafety incidents more visible and more consequential. When biosafety programs are underdeveloped or poorly integrated, the impacts quickly extend beyond technical operations and into enterprise performance.
A single biosafety incident can trigger operational shutdowns; regulatory scrutiny; loss of funding; legal liability; and risks to employee and public safety. These are not isolated technical issues; they are enterprise risks that affect continuity, reputation, and long-term viability. As a result, executives and boards are increasingly accountable to ensure that biosafety is not just present, but effective.
Research confirms that laboratory incidents are not rare and are rarely purely technical failures. A systematic review of laboratory-acquired infections identified hundreds of documented cases, many linked to procedural lapses, ineffective containment practices, and improper handling of biological materials (Dhawan et al., 2025). Similarly, broader policy analysis of global laboratory accidents shows that such incidents continue to occur regularly, with the majority attributed to avoidable human error and inadequate procedures, even in regulated environments (Ross & Harper, 2023).
Large-scale longitudinal analysis further reinforces this pattern. A study of 1,126 laboratory-associated incidents spanning 1900–2025 found that outbreaks and severe outcomes were most strongly linked to operational failures, including improper inactivation, aerosol leaks, and poor decontamination practices (Dhawan et al., 2026). These findings underscore a critical point: biosafety risk is systemic. It is shaped by how programs are designed, funded, and executed; not simply whether required procedures exist.
A clear example occurred in 2025 at the Integrated Research Facility at Fort Detrick, a high-containment laboratory capable of Biosafety Level 4 (BSL‑4) research on high-consequence pathogens (National Institute of Allergy and Infectious Diseases [NIAID], 2026). Operations were halted following a serious biosafety incident involving personnel misconduct, after a contractor damaged a colleague’s protective suit, potentially exposing them to dangerous pathogens and triggering federal investigation (Minnaugh, 2025). The event exposed vulnerabilities in safety culture and governance, demonstrating how quickly even highly controlled environments can escalate into enterprise risk.
Forward-looking organizations are reframing biosafety as part of their enterprise risk architecture, alongside cybersecurity, financial controls, and operational resilience. The question is no longer “Are we compliant?” but “Are we protected?”
Investors Are Expanding the Definition of Risk
Investor scrutiny is another major force elevating biosafety to the executive level. Across the life sciences sector, due diligence has expanded beyond scientific validity and market opportunity to include regulatory readiness, operational resilience, and governance effectiveness, reflecting a broader understanding of risk. Increasingly, biosafety and biosecurity risks are being captured within broader assessments of operational, regulatory, and governance risk. While investors may not evaluate biosafety as a standalone category, they are increasingly sensitive to the types of failures—safety incidents, compliance gaps, and governance breakdowns—that biosafety programs are designed to mitigate.
This shift is reinforced by the growing role of ESG—environmental, social, and governance—factors in investment decisions. ESG frameworks are widely used to evaluate how organizations manage risk and accountability beyond financial performance, incorporating considerations such as safety practices, governance quality, and operational transparency (CFA Institute, 2024). Institutional investor research shows that ESG is now widely used as a risk assessment lens, with strong emphasis placed on governance, transparency, and accountability as indicators of organizational resilience and oversight (CFA Institute, 2024; EY, 2024).
Investors are also demanding greater transparency, with organizations facing mounting pressure to provide reliable, decision-useful disclosures related to governance and risk management (EY, 2024; Miranda Partners, 2024). This growing emphasis on transparency and accountability reflects concerns about credibility and risk visibility, leading investors to place greater weight on demonstrated systems and governance maturity (Foley, 2025).
The result is a clear shift: while biosafety may not be evaluated explicitly, it increasingly influences how investors assess organizational maturity, scalability, and risk exposure. Organizations with strong, integrated biosafety systems signal discipline, operational control, and readiness for growth—qualities that attract confidence and investment interest. Conversely, gaps in biosafety can raise concerns about governance, execution, and risk management, potentially limiting investor confidence and slowing funding or partnership opportunities. This perspective is not limited to investors. It reflects a broader shift in how biosafety is being evaluated across regulatory, governmental, and global health frameworks.
Global Health Implications Are Reshaping Expectations
This perspective is not limited to investors. It reflects a broader shift in how biosafety is being evaluated across regulatory, governmental, and global health frameworks. The global environment has fundamentally changed how biosafety is perceived. In response to COVID‑19 and emerging disease threats, governments and international organizations are expanding biosafety into formal policy, regulation, and global governance frameworks.
International efforts such as updates to the International Health Regulations and the development of a Pandemic Agreement reflect increasing expectations for coordination, transparency, and preparedness at a global scale (WHO, 2024; WHO, 2025). These initiatives signal a move toward structured accountability, where both nations and organizations are expected to demonstrate effective biosafety systems.
At the same time, standardized approaches are gaining traction across sectors. ISO 35001, the international standard for biorisk management, is increasingly recognized as a framework for systematically identifying, assessing, and managing biological risk (ISO, 2019). Unlike traditional compliance-driven approaches, ISO 35001 positions biosafety as an integrated management system aligned with governance, operations, and organizational culture, supporting consistency, auditability, and continuous improvement.
National initiatives reinforce this trend. Programs such as the NIH Biosafety Modernization Initiative reflect the need to adapt oversight systems to rapidly advancing biotechnology (NIH, 2025). At the same time, global investment in pandemic preparedness, including laboratory infrastructure and surveillance systems, continues to expand through multilateral initiatives such as the Pandemic Fund, which supports capacity building across more than 100 countries, reinforcing that biological risk is shared and systemic (Pandemic Fund, 2026).
Together, these developments make clear that biosafety is no longer an internal operational concern. It is part of a global system of accountability, coordination, and risk management, where organizations are expected to demonstrate not just compliance, but capability, consistency, and control.
From Compliance to Strategic Integration
Despite this shift, many organizations still approach biosafety as a checklist exercise. Policies are written, training is conducted, and audits are passed; however, gaps persist because the program is not fully integrated into how the organization operates. Evidence consistently shows that biosafety incidents are not driven by missing requirements, but by breakdowns in execution, culture, and system design.
Research reinforces this point. Reviews of laboratory-acquired infections and biosafety incidents demonstrate that many events are linked to procedural lapses, inadequate training, and failures in implementation, rather than the absence of formal controls (Ross & Harper, 2023). These findings highlight a critical reality: biosafety performance depends on how systems function in practice, not simply how they are documented.
Leading frameworks are evolving accordingly. The World Health Organization emphasizes a risk-based, integrated approach that connects technical controls with training, procedures, and governance structures, recognizing that effective biosafety requires coordination across the entire organization (WHO, 2020). Similarly, ISO 35001 formalizes biosafety as a biorisk management system, requiring organizations to embed risk identification, mitigation, and performance monitoring into everyday operations rather than isolated compliance activities (ISO, 2019).
In practice, this means biosafety must be integrated into facility design and infrastructure; operational processes; governance structures; organizational culture; and budgeting and resource allocation, ensuring programs are sustainably funded and aligned with growth and risk exposure. At the board level, budgeting decisions ultimately determine whether biosafety is treated as a compliance obligation or a fully integrated risk management system.
Organizations that adopt this approach move beyond reactive correction and toward measurable performance. They align biosafety with how work is performed, creating systems that are resilient, scalable, and continuously improving. The distinction is clear: compliance ensures requirements are met; integration ensures biosafety actually works.
The Bottom Line
Biosafety is no longer confined to the laboratory. It is a defining component of organizational integrity, risk management, and long-term performance. As incident visibility increases, investor expectations evolve, and global accountability frameworks expand, biosafety has moved firmly into the realm of executive oversight.
Organizations that continue to treat biosafety as a technical afterthought will face increasing exposure to operational disruption, regulatory action, and reputational risk. By contrast, those that integrate biosafety into strategy, governance, and culture position themselves to manage risk proactively, scale responsibly, and maintain confidence among investors, regulators, and partners.
The distinction is no longer between compliant and noncompliant organizations—it is between those that have integrated biosafety into how they operate and those that have not.
The question is no longer whether biosafety belongs in the boardroom.
The real challenge is whether your organization is prepared to lead with it.
A Different Approach to Biosafety
At World BioHazTec, we don’t approach biosafety as a checklist, or as a theoretical exercise disconnected from operational reality. Our work is grounded in the direct evaluation of more than 300 laboratory programs, providing a clear understanding of where systems break down and why even capable organizations struggle to meet certification and performance expectations.
We partner with organizations to design and implement fully integrated biosafety systems, aligned with facility design, operational workflows, leadership oversight, and long-term growth. This ensures biosafety is embedded into how work is performed, rather than layered on after the fact.
Our focus is not just on compliance, but on system performance and how biosafety functions in practice, under pressure, and over time. In today’s environment, the presence of a program is not enough; its effectiveness determines the level of risk.
Biosafety is not just about passing an inspection. It is about protecting your people, your science, and your organization, while demonstrating the discipline, governance, and resilience expected by regulators, investors, and global stakeholders.
If biosafety has reached your boardroom, it’s time to manage it as a strategic system.
Works Cited
CFA Institute. (2024). What is ESG investing?
https://www.cfainstitute.org/insights/articles/what-is-esg-investing
Dhawan, S., Lim, P. L., Pan-ngum, W., MacIntyre, C. R., & Blacksell, S. D. (2025). Determinants of fatalities and secondary transmission in laboratory pathogen incidents, 1900–2025. The Lancet Microbe. https://doi.org/10.1016/S2666-5247(25)00085-0
Dhawan S, Muluneh A, Pan-gnum W et al. Risk factors and mitigation strategies of laboratory-acquired infections in research and clinical laboratories worldwide: a systematic review. The Lancet Microbe, 2025; 6
- (2024). Global Institutional Investor Survey.
Foley, M. (2025). How investors are driving ESG transparency. Forbes.
International Organization for Standardization (ISO). (2019). ISO 35001:2019 Biorisk management for laboratories and related organizations. https://www.iso.org/standard/71293.html
National Institute of Allergy and Infectious Diseases (NIAID). (2026). Integrated Research Facility at Fort Detrick. https://www.niaid.nih.gov/research/frederick-integrated-research-facility
Minnaugh, R. (2025). FBI investigates Fort Detrick lab incident as fight leads to potential pathogen exposure. https://thenationaldesk.com/news/americas-news-now/fbi-investigates-fort-detrick-lab-incident-as-fight-leads-to-potential-pathogen-exposure
Miranda Partners. (2024). Highlights from global corporate reporting survey.
Pandemic Fund. (2026). Strengthening pandemic prevention, preparedness, and response. https://www.thepandemicfund.org/
Ross, A., & Harper, K. (2023). Global biosecurity and laboratory safety risks. Chatham House.
Stanford Graduate School of Business, Hoover Institution, & MSCI. (2024). Institutional Investor Survey on Sustainability.
World Health Organization (WHO). (2020). Laboratory Biosafety Manual (4th ed.).
https://www.who.int
World Health Organization (WHO). (2024). International Health Regulations (amendments).
https://www.who.int
World Health Organization (WHO). (2025). Pandemic Agreement.
https://www.who.int
Featured Posts
What This Award Represents—and Why Biosafety Matters
By: Kerstin Haskell, MBA. President, World BioHazTec. I remember exactly where I was when I got the call. I was sitting in an airport, waiting for my flight home from Iceland after attending a conference in Germany. I was exhausted, jet-lagged, and only half paying attention to my phone when it rang. “Check your email!” said Carol Traum, our Executive Vice President. “Congratulations!” said Ted Traum, our Principal. “What are you talking about?” I asked. I was tired. “The award! You got it!” “Wait,” I said, suddenly more awake. “I’m going to meet the Governor?” That was the moment I learned I had been selected to receive the World Trade Center Institute Maryland International Business Leadership Award. It Started with a Conversation, Not a Campaign Like most meaningful recognition, this did not begin with a campaign or an application package. It started with a phone call from Brian Castleberry at the Maryland Department of Commerce—an exceptional partner who had helped bring Biosafety Day to Maryland the year before. He asked a few straightforward questions about our exports that year. “I’m putting you in for an award,” he said. “Oh, okay,” I replied, and rattled off some numbers. At the time, it didn’t feel momentous. In hindsight, it was one of those quiet inflection points that leadership careers are built on. Showing Up as a Team When the interview invitation arrived, the timing could not have been better. Dan Yoong, World BioHazTec’s Managing Director for Asia, the Middle East, and Africa, was already in the U.S. preparing for the ABSA International Conference. There was no question—Dan needed to be part of that interview. If we were being asked to speak about global impact, public health, and international collaboration, then he was a living example of that work. His wife joined us as well, as we were driving straight from the interview in Baltimore to Raleigh, North Carolina, for the conference. I will never forget that room—nearly fifteen people gathered around a conference table, introducing themselves. When it was Dan’s wife’s turn, she smiled and said, “I’m the boss of him,” pointing directly at Dan. The room immediately burst into laughter. Any nervousness disappeared. From there, we spoke openly and proudly about biosafety, engineering, partnership, and what it takes to build a company that crosses borders while remaining deeply rooted in Maryland. A Night That Felt Bigger Than One Person The awards ceremony at the M&T Bank Exchange was unforgettable. The room glowed with dramatic purple and blue hues, and for a moment, everything felt quietly surreal. Sitting to my left was my mentor, RADM Deborah Wilson, PhD, CBSP, RBP (ret.), with her husband, Tom, by her side. On my right was my husband, Jake. At our table were my parents, Ted and Carol Traum, long-time leaders and partners in World BioHazTec, alongside COO Juan Osorio and his wife Nathalie, and Lia Vizzotti, CEO of World BioHazTec Latin America. As I looked around the room, what struck me most was the scale. There were nearly 400 people in attendance—leaders from business, government, academia, and industry. Many of them had likely never heard the word biosafety before that evening. And yet, the work represented in that room—and far beyond it—depends on it. That realization stayed with me. Biosafety should not be a niche term known only to scientists and engineers. It should be recognized and embraced by C-suite executives, policymakers, investors, and institutional leaders as a foundational element of responsible innovation, public health preparedness, and economic resilience. If biosafety is invisible, it is vulnerable. If it is understood, it becomes integrated into decision-making at the highest levels. That sense of responsibility made the night feel larger than any single recognition. The People Who Brought Us Here That feeling deepened as women approached me throughout the evening—congratulating me, thanking me, and noting that I was the only woman among the six award recipients that year. Each time, I proudly introduced them to RADM Wilson and shared just how instrumental she has been in bringing so many of us together. From Ted’s early brainstorming sessions with RADM Wilson, to Juan Osorio—whom we met through colleagues in RADM Wilson’s orbit who recognized both his talent and the growing need for leadership in biocontainment engineering—to Lia Vizzotti, whom we met during a WHO-supported training session RADM Wilson helped organize, the throughline was RADM Wilson. She had an extraordinary ability to see what was needed and to connect people at exactly the right moment. We never forget that. Seeing Our Story on the Screen I will admit, I was nervous when the program began introducing each honoree and playing short videos about their work. I didn’t know what to expect when World BioHazTec appeared on the screen. You can watch the video here. What I saw was emotional, grounded, and deeply reflective of what our team has built over decades. When the video ended and I stood, the applause was immense—and humbling. A Conversation with the Governor When I met Governor Wes Moore, I thanked him for issuing Maryland’s Biosafety Day Proclamation—and, admittedly, asked whether we might be able to have another one. I asked him to connect me with his team so we could talk more about biosafety, its economic impact, and why Maryland is uniquely positioned as a global hub for high- and maximum-containment laboratories. We are a dense, interconnected community doing work that matters far beyond our borders. He was gracious, engaged, and genuinely curious. After confirming it was allowed, my husband stepped up to the stage. As we stood with Governor Wes Moore, he handed his phone to a woman nearby and asked, “Would you mind taking our picture?” I quickly interjected, “Jake, she is probably the CEO of some big company.” She laughed and replied, “Actually, I am the CEO of BWI Airport,” and graciously took our photo with the Governor. What This Award Represents This award is an honor—but more importantly, it is a responsibility. It reflects the collective work of World BioHazTec’s global team, the mentors who shaped us, the partners who trusted us, and Maryland’s leadership in biosafety and public health. The work continues, and we are proud to carry it forward—together. My hope is that leaders across industry, government, and policy will engage with biosafety not as a compliance obligation, but as a strategic responsibility that protects people, strengthens innovation, and safeguards our collective future.
Read More
Elevating Biocontainment Certification: World BioHazTec’s Engineering Approach
Ensuring the performance and safety of BSL-3 and ABSL-3 laboratories requires more than a checklist. It demands an engineering-based methodology that anticipates risk, verifies containment performance under both normal and abnormal operating conditions of critical laboratory systems, and delivers clear findings with actionable, technically sound recommendations to support facility leadership decision-making. At World BioHazTec, we have built our certification approach on that principle, combining deep technical rigor, licensed engineering oversight, and structured, decision-ready reporting. Expert-Led Certification, Not Technicians High-containment laboratories operate at a level of complexity where engineering judgment and field experience are critical. For that reason, we do not deploy technicians. Your facility is evaluated onsite by senior Subject Matter Experts (SMEs) who have assessed more than 200 biocontainment laboratories, contributed to biosafety guideline development, and presented internationally on certification practices and performance verification. This SME-led model ensures that subtle performance anomalies are accurately interpreted, risk assessments reflect operational realities, and recommendations are technically robust and strategically applicable to operations, maintenance, and Environmental Health and Safety (EHS) leadership. Engineered Assurance with PE Oversight World BioHazTec certification reports are reviewed and signed by a licensed Professional Engineer (PE). This provides technical authority, professional accountability, and regulatory defensibility to the findings and recommendations, giving stakeholders confidence that the report meets rigorous engineering standards. Comprehensive Methodology, Beyond the Baseline Baseline certification includes: Document review Interior inspection Differential pressure verification during normal/abnormal laboratory operation Verification of calibration of installed instrumentation Performance testing under normal operating conditions Performance testing under critical system failure scenarios Quantitative directional airflow verification Functional alarms confirmation World BioHazTec goes beyond the baseline by including: Exterior building inspection Thermal imaging Differential pressure trend analysis SME-led risk assessment Structured quality improvement recommendations Remote notification system verification One-year expert access Decision-Ready Reporting Our reports are structured to support executive and operational decision-making. Data related to pressures, airflow behavior, and alarm performance are presented alongside engineering interpretation, risk analysis, and clearly defined corrective and preventive actions. Fail-Forward: Proactive Failure Scenario Testing World BioHazTec conducts controlled failure scenario testing during laboratory operation to strengthen system reliability, not merely to record pass/fail results. Airflow behavior under upset conditions is thoroughly documented, with SME-led evaluations guiding risk-based corrective actions. Independence from BAS-Generated Graphs World BioHazTec does not rely solely on Building Automation System (BAS) trend graphs. BAS trend logs may be limited by server bandwidth restrictions or legacy system constraints, which can obscure or oversimplify critical airflow behavior or differential pressure relationships between areas, variables essential for containment integrity. Instead, we use certified and calibrated instruments to obtain independent measurements, ensuring that the data presented is precise, high-resolution, and fully representative of actual critical system performance. This approach provides engineering-grade documentation that stands independently of automation system limitations. Report Clarity and Usability Clear communication is essential in high-containment facilities, where decisions impact safety, operations, and long-term system reliability. Our reports are intentionally designed to be precise, structured, and easy to navigate. We focus on relevant information presented clearly and directly. We avoid excessive narrative, redundant data, and confusing diagrams. Each report follows a logical structure that directs the reader to key findings. Data is presented using clear photographs, defined graphs, and well-labeled diagrams that quickly identify what is functioning properly, what requires attention, and what actions are recommended. This clarity ensures documentation that is technically rigorous, practical, and ready for audits, internal reviews, and operational planning. Lifecycle Partnership, Not a One-Time Event High-containment environments evolve as equipment ages, operations change, and research requirements shift. Our one-year complimentary expert access ensures continued technical support beyond the certification visit. Why This Matters for BSL-3 / ABSL-3 Facilities A comprehensive certification approach provides: · Greater system reliability · Clear documentation for audits and regulatory compliance · Early identification of vulnerabilities · Trend analysis to support maintenance and upgrade planning · Stronger technical support for leadership decisions Beyond Compliance: The World BioHazTec Philosophy Compliance is the starting point. Our goal is engineered assurance, ensuring that the facility performs as intended, especially during off-normal events. Ready to learn more? Contact us for a free consultation.
Read More
Design Pitfalls in Biocontainment Laboratories: Lessons from Real Projects
Building a biocontainment laboratory—whether BSL-3, ABSL-3 or ACL-3, is a highly specialized process that requires careful planning and coordination. When design decisions are made without early input from Subject Matter Experts (SMEs), critical issues often surface late in the project, leading to costly changes and delays. Below are examples of common challenges identified during design reviews and commissioning phases. These illustrate why early integration of biosafety and engineering expertise is essential. Example 1: Missing Containment Features In one recent project, a design review uncovered a critical oversight. The Basis of Design (BOD)—the document outlining the institution’s requirements for the laboratory—specified that the facility would support research involving avian influenza. However, the design did not include provisions for a shower-out protocol or the necessary plumbing infrastructure to accommodate a future effluent decontamination system, both of which may be required by evolving regulations. This omission significantly limited the laboratory’s operational capabilities, restricting it to work with agents that do not require a shower-out process. Ultimately, substantial redesign was needed to bring the project back into alignment with the BOD and ensure long-term compliance and flexibility. Other issues included: In a BSL-3 setting, undefined personnel pathways and workflows create unclear boundary separations, increasing the risk of containment breaches, procedural confusion, and noncompliance biosafety requirements. Insufficient clearance for biosafety cabinets (BSCs) in isolation spaces. Doors swinging against intended airflow direction. Use of inappropriate sealing materials for penetrations. Inclusion of a fume hood for chemical work instead of a Class II Type B2 BSC. Incomplete risk assessment during early design phases. Insufficient attention to maintenance access and laboratory equipment placement. Structural limitations in the room envelope made it unable to safely tolerate deep negative pressure conditions. Impact: These oversights affected containment integrity and workflow efficiency, requiring structural changes late in the process. Example 2: Airflow and Equipment Integration During commissioning of a facility under construction, several design gaps were identified: A BOD change required upgrading the Class II BSC from Type A2 to Type B2, but the existing exhaust fan curves could not support the increased airflow demand. Lack of exhaust ducting over the autoclave chambers to manage heat and connecting to the BSL-3 exhaust ductwork. Freezer placement in a concentrated area not accounted for in the air distribution. Provision for decontaminating large equipment before removal. Autoclave bioseal ordered for the wrong side with the master control on the wrong side. Impact: These issues prolonged commissioning, delayed the project schedule, and resulted in substantial change-order claims. Example 3: HVAC and Containment Compliance In another case, evaluation of arthropod containment labs revealed: Omission of supply and/or exhaust air in anterooms. Misinterpretation of containment guidelines led to improper combining of BSL-2 and BSL-3 exhaust ductwork. Non-airtight ceiling access doors and introducing unaccounted infiltration affecting directional airflow. HVAC airflow reversals during failure testing created unacceptable containment risks. Impact: These deficiencies increased the risk of containment loss, with airflow reversals posing the greatest safety threat and pest intrusion creating major USDA compliance concerns. Top 6 Design Principles for Biocontainment Labs To avoid these pitfalls, consider these foundational principles during the earliest stages of design: 1.Define the Research Capabilities of the Laboratory Clearly defining laboratory intent in the Basis of Design is essential to ensure the facility is engineered to meet its functional, safety, and regulatory requirements. 2. Define Containment Boundaries Clearly Establishing primary, secondary, and tertiary barriers in relation to workflow early ensures the laboratory’s containment strategy is clear, coordinated, and integrated into the design from the start. This prevents costly redesigns, reduces construction risk, and supports reliable, compliant biocontainment performance. 3. Plan for Directional Airflow and Pressure Differentials Ensure airflow moves from clean to contaminated areas, with validated pressure relationships and redundancy in HVAC systems. 4. Integrate Equipment into Design Account for biosafety cabinets, autoclaves, and other critical equipment in spatial layouts and airflow calculations to ensure sufficient make-up air and proper cooling and heat-load dissipation. 5. Design for Maintenance and Decontamination Include provisions for safe removal and decontamination of large equipment and keep serviceable maintenance items outside of containment where possible. 6. Follow Risk-Based Guidelines and Standards Align with Biosafety in Microbiological and Biomedical Laboratories (BMBL), NIH Design Requirements Manual, WHO Laboratory Biosafety Manual and other relevant standards to ensure compliance and operational safety from the start. The Bottom Line Early engagement with World BioHazTec’s SMEs ensures: Compliance from the start with WHO, CDC, NIH, ANSI/ASSP Z9.14-2014 and other applicable guidelines. Cost savings by avoiding late-stage redesigns. Operational efficiency through risk-based design and redundancy planning. Don’t wait until commissioning to discover design flaws. Partner with World BioHazTec early and build a laboratory that meets the highest standards of safety and functionality. Ready to start your project right? Contact us for a free consultation.
Read More
